Introduction {#s1}
============

In the last decade, the prevalence of obesity \[body mass index (BMI; calculated as weight in kilograms divided by height in meters-squared) ≥ 30\], among adult Americans was 35%, and is expected to increase in years to come \[[@B1]\]. Type 2 diabetes mellitus (DM) is an important problem among the obese. Overweight (BMI 25--29.9), obese (BMI 30--39.9), and extremely obese (BMI \> 40) American adults had 1.59, 3.44 and 7.37 times higher odds, respectively, of diagnosed DM \[[@B2]\]. Obesity and DM in unison create enormous health care costs, of which the direct and indirect costs of pharmacotherapy plays a major role \[[@B3]\].

Intentional weight loss, by decreasing insulin resistance, is associated with better glycemic control \[[@B4],[@B5]\] and consequently a decrease in the need for anti-diabetic medications \[[@B6]\]. However, it is well known that not everyone who loses weight is successful in reducing anti-diabetic medications \[[@B6]\]. Hence, a clinically applicable screening tool that can predict success with dose reductions of anti-diabetic medications would be useful, and could help motivate patients, as well as assist practitioners in patient counseling, and individualizing the intensity of weight loss intervention for a given obese patient attempting weight loss. Since insulin resistance is the central pathophysiology behind obesity-associated diabetes, we hypothesized that a marker of insulin resistance, measured at the onset of weight loss efforts, might serve as a screening tool to predict success with dose reductions of anti-diabetic medications accompanying successful weight loss. Tryglyceride (TGL)/HDL ratio is a known marker of insulin resistance \[[@B7]\]. To test this hypothesis, we studied overweight and obese patients from 2 University-based weight management programs, analyzing the relationship between triglyceride/HDL ratio and success in reducing anti-diabetic medications.

Materials and Methods {#s2}
=====================

Study setting and design {#s2.1}
------------------------

This retrospective cohort study was conducted in two, University based, specialty, outpatient weight management clinics, the Johns Hopkins Weight Management Center in Baltimore, MD, and the George Washington Weight Management program in Washington, DC. Institutional review board approval was obtained from Johns Hopkins University institutional review board for conducting the study. Informed consent was not obtained from the participants, as the data was analyzed anonymously per institutional review board guidelines. Institutional review board waived the need for written informed consent from the participants.

Case records of patients with BMI \> 25 kg/m^2^ at the time of enrollment into the two weight management programs during the period March 2008 to January 2012 were assessed for eligibility. The study cohort consisted of patients with a diagnosis of DM at the time of enrollment who reported taking anti-diabetic medications. Patients were excluded if they did not have a diagnosis of DM at the time of enrollment into the programs.

Baseline data collection {#s2.2}
------------------------

Demographic data (age, gender, race/ethnicity), cardiovascular risk factors (smoking, diabetes, hypertension), medication history (anti-diabetic medications, anti-hypertensive medications, and lipid-lowering drugs), clinical parameters (height, weight, systolic blood pressure (SBP) and diastolic blood pressure (DBP), and laboratory parameters (fasting glucose, HbA1c, total cholesterol, low-density lipoprotein cholesterol (LDL), high-density lipoprotein cholesterol (HDL), triglycerides) were collected from the study cohort. BMI was calculated as per standard guidelines \[[@B8]\]. DM was identified by physician diagnosis.

Patient follow-up and weight management intervention details {#s2.3}
------------------------------------------------------------

The weight loss intervention protocols followed at the two participating clinics were similar, and consisted of team-based, comprehensive evaluation and treatment for weight loss. The study participants had physician visits for follow-up twice a month on average. The baseline visit consisted of a physician-conducted medical history and physical examination, blood tests (as described above), and detailed dietary, behavioral, and exercise evaluations. Treatment was individualized, but typically consisted of an approximately 1000 kcal/day energy-deficit diet, often utilizing meal replacements, a behavior modification plan, and a plan for increasing physical activity utilizing both aerobic exercise and strength training. These interventions with diet, physical activity and behavior modification were similar in both participating institutions. Depending on treatment response, the intervention was tailored to address individual patient needs. The decision to alter the dose of or discontinue anti-diabetic medications was based on the clinical judgment of the treating physicians. Factors considered in deciding on dose reductions included magnitude of weight loss, glycemic control, hypoglycemic symptoms, and the patient's compliance with the weight management protocol.

Triglyceride/HDL ratio cutoffs tested as screening tool {#s2.4}
-------------------------------------------------------

Triglyceride/HDL ratios of all study cohort participants at the time of their enrollment into the weight management programs were calculated. Cutoffs for triglyceride/HDL ratio of ≤ 2, ≤ 2.5, ≤ 3, ≤ 3.5, and ≤ 4.0 were evaluated to determine which cut-off value yielded optimal results as a screening tool. Using these baseline triglyceride/HDL cutoffs, each member of the study cohort was categorized, within each cutoff category, as successful or unsuccessful in achieving at least one dose reduction of any anti-diabetic medication by study exit. Patients exited the study if they achieved at least 1 dose reduction of any of their anti-diabetic medications, or at study conclusion in January 2012. One dose reduction was defined as any recorded decrease in dose of anti-diabetic medication, which included lowering the dose or completely stopping that particular medication.

Testing reproducibility of the triglyceride/HDL ratio {#s2.5}
-----------------------------------------------------

Three of the authors were involved in this experiment. One of them was an internist with 5 years' post medical school experience; one was a MD with 3 years' post medical school experience and third was a diabetes educator with 1 year post bachelors degree experience. All three authors received a brief 20 minutes training regarding calculation of triglyceride/HDL ratio. A computer generated random sample (n = 60) from the study cohort was selected. First the internist calculated baseline triglyceride/HDL ratio for this random study cohort patients, blinded with regard to patient and medication history. To test intra-observer correlation, the internist recalculated baseline triglyceride/HDL ratio, for the same random sample of study cohort participants after 1 week, blinded with regard to earlier triglyceride/HDL ratio results, patient and medication history. Correlation was calculated comparing the present and previous findings of the internist. Then, the MD calculated baseline triglyceride/HDL ratio for the same random sample used by the internist, blinded with regard to patient, medication details and triglyceride/HDL ratios. Correlation was calculated comparing the triglyceride/HDL ratios of the internist with that of the MD. Similarly, the diabetes educator calculated triglyceride/HDL ratio for the same random sample and correlation was calculated comparing her findings with that of the internist.

Statistical analysis {#s2.6}
--------------------

Data was expressed in number (%) for categorical variables, and as mean ± standard deviation for continuous variables. The baseline characteristics of study cohort participants who successfully dose reduced anti-diabetic medications were compared with the study cohort participants who were not successful with even 1 dose reduction of any anti-diabetic medications, using Student's t test and chi-squared tests, as appropriate. Similarly, these 2 groups were compared with regard to magnitude of weight loss and HbA1C% reduction by study exit.

Multiple linear regression analysis and multiple logistic regression analysis were performed with magnitude of weight loss (kg) and dose reductions of anti-diabetic medications (coded as a dichotomous variable) as dependent variables. Age, gender, hypertension diagnosis, smoking, lipid lowering medication use, duration of diabetes, baseline BMI and TGL/HDL ratio were independent variables. In addition, logistic regression analysis assessing association between dose reductions of anti-diabetic medications and TGL/HDL ratio was adjusted for magnitude of weight loss.

To assess if triglyceride/HDL ratio is an effective screening tool to predict success with dose reductions of anti-diabetic medications, sensitivity, specificity, positive predictive value, negative predictive value, likelihood ratio of positive test, likelihood ratio of negative test and area under the receiver operating characteristics curve (ROC) were calculated, using standard methods, for the cut-off points for triglyceride/HDL ratios \[[@B9]\]. Also, TGL/HDL ratio was coded as continuous variable and AUC was computed. Kappa statistics was used to assess intra- and inter-observer agreement in interpreting triglyceride/HDL ratios \[[@B9]\]. A P-value of \<0.05 was considered statistically significant. Statistical analyses were performed using Stata 11.0 statistical software \[[@B10]\].

Results {#s3}
=======

In total, 179 patient records (107 from Johns Hopkins and 72 from George Washington) were identified and reviewed. Of these, 58 (32%) were excluded (excluded cohort) because they did not have a diagnosis of diabetes at the time of enrollment into the programs. The remaining 121 (68%) with a diagnosis of diabetes formed the study cohort. All study cohort patients were taking one or more anti-diabetic medications at the time of enrollment. Demographic characteristics and medication details of the study cohort and excluded cohort are shown in [Table 1](#tab1){ref-type="table"}. Follow-up details of the study cohort by study exit are detailed in [Table 2](#tab2){ref-type="table"}.

###### Baseline characteristics of the study cohort.

  Variables                      Study cohort   Successful\#   Not successful[\*](#ngtab1.2)   P-value
  ------------------------------ -------------- -------------- ------------------------------- ---------
                                 (n = 121)      (n = 81)       (n = 40)                        
  Age (yrs)                      51.8 ± 8.9     52.7 ± 9.1     53.7 ± 9.3                      0.133
  Males --n (%)                  67 (55)        45 (56)        22 (55)                         0.668
  Caucasians --n (%)             90 (74)        63 (78)        27 (68)                         0.042
  African Americans --n (%)      31 (26)        18 (22)        13 (32)                         0.044
  Current smoking --n (%)        24 (20)        16 (20)        8 (20)                          0.996
  Duration of diabetes (yrs)     7.5 ± 2.5      8.0 ± 2.0      7,5 ± 2.0                       0.371
  Mean baseline weight (Kgs)     126.5 ± 18.2   127.1 ± 16.4   126.9 ± 19.3                    0.417
  Mean BMI (kg/m^2^)             36.1 ± 6.2     36.1 ± 5.5     35.6 ± 4.7                      0.226
  BMI: 25-30 --n (%)             30 (25)        23 (28)        7 (18)                          0.047
  BMI: 31-40 --n (%)             64 (53)        51 (63)        13 (33)                         0.021
  BMI ≥ 41 -- n (%)              27 (22)        7 (9)          20 (50)                         0.017
  HbA1C %                        8.2 ± 1.6      8.1 ± 2.3      8.0 ± 1.7                       0.179
  Mean TC (mmol/l)               5.2 ± 1.3      5.2 ± 1.1      5.1 ± 1.7                       0.113
  Mean LDL -- C (mmol/l)         4.2 ± 1.3      4.0 ± 1.4      4.1 ± 1.2                       0.091
  Mean HDL -- C (mmol/l)         1.2 ± 0.4      1.1 ± 0.3      1.1 ± 0.4                       0.216
  Mean TGL (mmol/l)              1.7 ± 0.3      2.0 ± 0.5      1.9 ± 0.6                       0.166
  Mean TGL/HDL ratio             2.9 ± 1.2      3.1 ± 0.8      2.8 ± 1.1                       0.051
  HTN diagnosis --n (%)          102 (84)       69 (85)        33 (83)                         0.067
  MS --n (%)                     68 (56)        45 (56)        23 (58)                         0.116
  Lipid lowering drugs --n (%)   91 (75)        64 (79)        27 (68)                         0.055
  Statins                        91 (75)        64 (79)        27 (68)                         0.055
  Atorvastatin                   52 (43)        27 (33)        25 (63)                         0.172
  Pravastatin                    24 (20)        13 (16)        11 (28)                         0.133
  Rosuvastatin                   15 (12)        8 (10)         7 (18)                          0.226
  Fenofibrate                    7 (6)          4 (5)          3 (8)                           0.417
  Anti -- HTN drugs --n (%)      102 (84)       69 (85)        33 (83)                         0.067
  Metformin-n (dose/day)         71 (1.7g)      51 (1.7g)      20 (1.7g)                       0.044
  Sulphonylureas-n (%)           59 (49)        40 (49)        19 (48)                         0.133
  Glyburide-n (dose/day)         24 (10mg)      16 (10mg)      8 (10mg)                        0.091
  Glipiside-n (dose/day)         21 (10mg)      12 (10mg)      9 (10mg)                        0.046
  Glymipride-n (dose/day)        14 (2-4 mg)    9 (2-4 mg)     5 (2-4 mg)                      0.117
  Sitagliptin-n (dose/day)       19 (100 mg)    11 (100 mg)    8 (100 mg)                      0.061
  Insulin-n (dose/day)           59 (60 U)      45 (65 U)      14 (60 U)                       0.155

\#Study cohort participants successful with dose reductions

Study cohort participants not successful with dose reductions

###### Follow-up details of the study cohort.

                          Study cohort   Successful\#   Not successful[\*](#ngtab2.2)   P value
  ----------------------- -------------- -------------- ------------------------------- ---------
  Follow-up (months)      12.5 ± 3.5     13.0 ± 2.5     12.5 ± 2.5                      0.511
  Baseline weight (Kgs)   126.5 ± 18.2   127.1 ± 16.4   126.9 ± 19.3                    0.417
  Final weight (Kgs)      110.3 ± 5.9    108 ± 11.2     117 ± 5.7                       0.031
  Weight loss (Kgs)       15.4 ± 5.5     16.9 ± 4.7     9.2 ± 3.1                       0.029
  Baseline HbA1C%         8.2 ± 1.6      8.1 ± 2.3      8.0 ± 1.7                       0.179
  Final HbA1C%            7.7 ± 0.3      7.4 ± 0.6      7.9 ± 0.2                       0.039
  Change in HbA1C%        0.5 ± 0.2      0.7 ± 0.2      0.2 ± 0.1                       0.035

\#Study cohort participants successful with dose reductions

Study cohort participants not successful with dose reductions

By study exit, 81 (67%) in the study cohort achieved at least 1 dose reduction of any anti-diabetic medication. The remaining 40 (33%) in the study cohort failed to achieve even 1 dose reduction of their anti-diabetic medication; their weight loss and HbA1c% reduction was significantly less than those in the study cohort who did successfully dose-reduce anti-diabetic medications ([Table 2)](#tab2){ref-type="table"}.

Baseline BMI and TGL/HDL ratio had a strong and independent association with magnitude of weight loss and dose reductions of anti-diabetic medications ([Table 3)](#tab3){ref-type="table"}.

###### Factors associated with magnitude of weight loss and success with dose reductions.

  Variables                        Magnitude of weight loss (Kgs)\#   Dose reductions[\*](#ngtab3.2)                         
  -------------------------------- ---------------------------------- -------------------------------- --------------------- -------
  Age                              1.57 (-0.11 -- 3.11)               0.136                            1.01 (0.77 -- 2.32)   0.216
  Gender                           0.91 (-0.62 -- 2.17)               0.133                            1.15 (0.67 -- 2.37)   0.210
  Hypertension                     2.45 (-0.12 -- 3.16)               0.133                            0.96 (0.42 -- 1.92)   0.132
  Smoking                          1.45 (-1.50 -- 3.63)               0.511                            1.07 (0.66 -- 2.11)   0.286
  Lipid lowering medication use    0.97 (-1.10 -- 2.36)               0.162                            1.13 (0.71 -- 1.96)   0.149
  Baseline BMI                     1.53 (0.58 -- 2.27)                0.033                            1.47 (1.14 -- 2.35)   0.031
  TGL/HDL ratio                    5.28 (1.51 -- 8.13)                0.014                            1.31 (1.03 -- 2.41)   0.022
  Duration of diabetes (yrs)       1.10 (-2.74 -- 3.71)               0.159                            1.14 (0.68 -- 2.66)   0.291
  Magnitude of weight loss (kgs)   \-                                 \-                               1.18 (1.09 -- 1.96)   0.031

OR: Odds Ratio; β: Linear regression coefficient; C.I: confidence interval,

\#multi-variate linear regression analysis

multi-variate logistic regression analysis

Tests for TGL/HDL ratios as a screening tool to predict success with dose reductions of anti-diabetic medications is shown in [Table 4](#tab4){ref-type="table"}. When TGL/HDL ratio was coded as a continuous variable AUC was 82. Of the selected cut-off values, TGL/HDL ratio ≤ 3 showed optimal results with a sensitivity, specificity, positive predictive value, negative predictive value, AUC, LR + and LR-of 81, 83, 90, 70, 78, 4.8 and 0.2 respectively ([Table 4)](#tab4){ref-type="table"}. ROC curves can be viewed in [Figure S1](#pone.0069285.s001){ref-type="supplementary-material"} and [Figure S2](#pone.0069285.s002){ref-type="supplementary-material"}. Further, kappa statistics for intra-observer agreement was 0.99 and Inter-observer agreement between the internist and the MD was 0.99 and between the internist and the diabetes educator was 0.99.

###### TGL/HDL ratio as a screening tool to predict success with dose reductions.

  Parameters          TGL/HDL ratio                     
  ------------------- --------------- ----- ----- ----- -----
  Sensitivity (%)     20              41    81    85    88
  Specificity (%)     95              85    83    58    35
  PPV                 89              85    90    80    73
  NPV                 37              41    70    66    58
  AUC                 51              62    78    65    53
  LR+                 4.0             2.7   4.8   2.0   1.4
  LR-                 0.8             0.7   0.2   0.2   0.3
  Number successful   16              33    66    69    71
  Total               18              39    73    86    97

Discussion {#s4}
==========

Our study of overweight and obese adults has identified TGL/HDL ratio as a potentially effective screening tool to predict success with dose reductions of anti-diabetic medications in patients who successfully lose weight.

We found, not surprisingly, that magnitude of weight loss was an important factor determining success with dose reductions of anti-diabetic medications ([Table 2)](#tab2){ref-type="table"}. Mechanistically, weight loss is accompanied by decreasing insulin resistance and hence better glycemic control \[[@B11]\]. This could explain the strong and independent association of TGL/HDL ratio, a marker of insulin resistance \[[@B7]\], with magnitude of weight loss, and thus with the higher probability of dose reductions of anti-diabetic medications that was observed ([Table 3)](#tab3){ref-type="table"}. This reasoning comports with our rationale for the use of TGL/HDL ratio as a screening tool to predict success with dose reductions of anti-diabetic medications. Prior studies have also shown TGL/HDL ratio to positively correlate with adiposity, and its decrease proportional to magnitude of weight loss \[[@B12],[@B13]\].

Further, 75% of our patients were using lipid lowering medications at baseline ([Table 1)](#tab1){ref-type="table"}. However, the observed independent association of TGL/HDL ratio with dose reductions of anti-diabetic medications even after adjusting for lipid lowering medication use ([Table 3)](#tab3){ref-type="table"} highlights the potential use of TGL/HDL ratio as a screening tool to predict success with dose reductions of anti-diabetic medications irrespective of lipid lowering medication use.

We note that when a screening tool is assessed for its predictive accuracy, the prevalence of the event of interest should be taken into consideration \[[@B14]\]. When the prevalence of the event of interest (dose reductions of anti-diabetic medications) is high (67% in our study), values of sensitivity, specificity, positive predictive value and negative predictive value may be less useful for clinical application, since all of the above-mentioned indicators of test accuracy vary with prevalence. In this context, the indicators of test accuracy which do not significantly vary with prevalence are the most clinically relevant. LR+ and LR-do not vary with prevalence of the disease \[[@B14]\]. An LR+ \>1 and an LR− \<1 makes a diagnostic test clinically meaningful, while a LR+ \>10 and LR− \<0.1 indicates very high accuracy \[[@B14]\]. In our study, among all arbitrary TGL/HDL ratio cut-offs assessed, TGL/HDL ratio ≤ 3, with its LR+ of 4.8 and LR-was 0.2, had the highest predictive accuracy. Area under the ROC curve of 78% also conveys the same meaning. Combined with its good reproducibility, TGL/HDL ratio may well be a clinically useful screening tool for this purpose. Interestingly, TGL/HDL ratio has been found in other studies to be an effective tool for predicting gestational diabetes \[[@B15]\], cardiovascular risk in patients with familial hypercholestrolemia \[[@B16]\], atherogenic apolipoprotein B levels \[[@B17]\] and as a surrogate marker in the mechanistic pathway through which pioglitazone possibly delays coronary atheroma progression in diabetic patients \[[@B18]\].

Limitations {#s4.1}
-----------

We observed significantly greater magnitudes of weight loss (15.4 kgs by 15 months of follow-up) compared to typical randomized, controlled weight loss trials (RCTs) (weight loss: 4--6 kgs within 12-15 months of follow-up, SBP/DBP: 3-4/2-3 mmHg) \[[@B19],[@B20]\]. It is thus possible that confounding due to unknown factors may have played a role. Or, surveillance bias is possible, due to the intensity of weight loss intervention being individualized, and the decision to dose reduce being subjective and at the discretion of the treating physicians. Also, small sample size limited us from analyzing our research question with individual anti-diabetic medications and individual BMI classes. Further, convenience sampling may have led to selection bias. Retrospective cohort design limited us to what was recorded in patient charts; for example, we did not have date on waist/hip ratio, which might also have relevance as a predictor.

Conclusions {#s5}
===========

In conclusion, TGL/HDL ratio was found to show promise as a clinically applicable screening tool. It showed moderately high accuracy in predicting success in reducing use of anti-diabetic medications among overweight and obese diabetics attempting weight loss. Further, it is easy to calculate and has good reproducibility. Before advocating widespread use, this tool should be prospectively validated in future RCTs or clinical settings, and evaluated in systematic reviews using data that is available from completed RCT's \[[@B19],[@B20]\].
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###### ROC curve for TGL/HDL ratio ≤ 3 as a screening tool to predict success with dose reductions of anti-diabetic medications.
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###### ROC curve when TGL/HDL ratio was coded as continuous variable.
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